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Recurrent respiratory papillomatosis or recurrent laryngeal papillomatosis is a disease of the 
larynx caused by human papilloma virus, characterized by verrucous epithelial lesions and usually 
recurring. In the literature there are several types of treatment, such as surgery to cold, laser and/or 
use of microdebrider, as of adjuvant therapies; all possible to decrease the permanent sequelae of 
the disease.
Objective: To review the literature regarding this disease with emphasis on surgical techniques and 
adjuvant therapies used today.
Method: We used the literature review, through surveys based electronic data in the public domain, to 
search for articles between 1992-2012, using keywords: papilloma, human pappiloma virus infection, 
larynx, therapeutic, papilloma virus vaccine.
Results: We surveyed 357 articles, of which 49 were used as the basis for this review. Scientific 
studies indicate a reduction of relapse in most adjuvant therapeutic presented. However, the survey 
showed different methodologies and samples, which did not allow to compare the types of treatment 
and adjuvant therapies.
Conclusion: The choice of surgical technique varies among studies, but there is a trend to use the 
microdebrider. The newer adjuvant therapies, such as cidofovir, quadrivalent vaccine against human 
papilloma virus and bevacizumab, require further studies.
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INTRODUCTION
Recurrent respiratory papillomatosis (RRP) or 
laryngeal papillomatosis is a laryngeal disease caused 
by the human papilloma virus characterized by the 
proliferation of recurring epithelial wart-like lesions called 
papillomas. Papillomas commonly relapse and occur in 
significant numbers1,2. RRP is the most frequently seen 
benign laryngeal tumor. Confluent papillomas introduce 
significant morbidity and may lead to dysphonia (voice 
alteration) and dyspnea (respiratory pattern alteration)2,3.
RRP results from infection by the human papilloma 
virus (HPV). The most often detected virus subtypes are 
HPV-6 and HPV-11, seen in approximately 90% of the 
cases1,2. HPV-16 and HPV-18 are found more rarely in 
children with RRP3, and have been more strongly correlated 
with malignant disease.
The mode of transmission of HPV has not been 
clearly established. Although transmission by sexual 
intercourse has been described, possible nonsexual 
routes include vertical and horizontal transmission, 
and autoinoculation. A recent meta-analysis showed 
that vertical transmission accounts for approximately 
20% of the cases of HPV. However, horizontal 
transmission through saliva or other means has also 
been described2,4. Upper airway exposure to HPV-6 
and HPV-11 occurs somewhat frequently during one’s 
life. It is likely that exposure to HPV is as common 
as exposure to other viruses, as studies have detected 
HPV DNA in the upper airways of as many as 25% of 
unaffected children and adults5.
According to Derkay6, some 1,500 to 2,500 new 
cases of RRP are diagnosed in the United States every 
year. Tasca et al.7 have reported an incidence of 6.9 cases 
for every 1,000 babies born from mothers with history 
of genital warts, against no cases per 1,000 births of 
children from mothers without history of genital warts. 
The authors have also reported that risk of RRP in children 
born from mothers with papillomas during pregnancy 
is 231.4 times higher than in mothers without history of 
papilloma. Incidence rates have been estimated at 4.3 
cases for every 100,000 children and 1.8 case for every 
100,000 adult subjects6.
The disease is usually categorized according to 
the severity of the signs and symptoms, and is divided 
into aggressive and non-aggressive RRP. Aggressive RRP 
is characterized by the need for ten or more surgical 
procedures, with three or more procedures being 
performed within the period of one year, or by when 
the disease extends distally toward the subglottic airway. 
Contrastingly, non-aggressive RRP is characterized by the 
need for fewer than ten procedures, with fewer than three 
procedures being performed within the period of one year, 
or no distal involvement reaching the subglottic area8.
Diagnosis is performed with the aid of fibroscopy 
(flexible scope) and laryngoscopy (rigid scope) and 
confirmation is attained through pathology testing. 
Macroscopically, laryngeal papillomas are pedunculated 
uneven nodular tumors of varying sizes. In terms of 
histology, papillomas are extremely vascularized, often 
keratinized tumors made of connective tissue covered by 
stratified squamous epithelium that project outwardly in 
finger-like fronds9.
Treatment is designed to maintain airway 
patency, improve patient voice quality, and prevent 
against complications. Surgery is the therapy of choice 
for RRP. Cold microsurgery, laser microsurgery, or 
surgery with a microdebrider are used to spare healthy 
tissue, prevent the formation of scar tissue, and remove 
all papillomas1,10. Nonetheless, surgery cannot prevent 
recurrence, thus opening a precedent for the use of 
adjuvant therapies.
Adjuvant therapies have been given significant 
attention in the realm of RRP care. Many treatments 
have been described in the literature, but none 
appear to provide patients with a cure. Palliative 
care has been offered in the form of interferon-alpha, 
indole-3-carbinol, photodynamic therapy, cis-retinoic 
acid, cidofovir, aciclovir, ribavirin, bevacizumab, and 
tetravalent HPV vaccine6-19.
There still is no consensus on the best course of 
adjuvant therapy. This study aimed to review the literature 
on RRP and focus on the most frequently used surgical 
approaches and adjuvant therapies.
METHOD
The literature review was carried out based on 
the following question: ‘what are the surgical procedures 
and adjuvant therapies currently used in the treatment 
of recurrent respiratory papillomatosis?’. The search was 
carried out on databases Cochrane, LILACS (Literature in 
the Health Sciences in Latin America and the Caribbean), 
MedLine (USA National Library of Medicine), PubMed, and 
SciELO for papers written between January of 1992 and 
November of 2012. The following keywords were used in 
the search for papers: papilloma, papillomavirus infection, 
larynx, therapy, papillomavirus vaccines. Only papers writ-
ten in Portuguese, Spanish, and English were included.
The papers found in the initial search were 
independently assessed by two authors. In order not 
to exclude important studies from the review, after 
a consensus meeting the two reviewers selected all 
potentially relevant papers accompanied or not by their 
abstracts. After the selection of relevant titles, papers in 
full were collected and assessed based on a protocol 
considering the following topics: type of study, sample, 
adopted approach, and reported results. All cross-sectional, 
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longitudinal, prospective, and retrospective clinical trials, 
review papers, meta-analyses, case reports, and chapters 
published in Brazilian books meeting the criteria were 
included. Papers with significantly similar contents were 
excluded, and priority was given to the first authors 
to publish on the topic on Brazil or abroad, and/or to 
papers with larger and more recent samples. Included 
studies were chosen based on how well they answered 
the guiding question of this literature review. The book 
chapter selected for this review was chosen from a recent 
publication of 2011.
RESULTS
Forty-nine of the 357 papers listed in the search 
result were included in this literature review. Most 
authors reported less recurrence with surgery and 
adjuvant therapy combined. However, the differences 
in materials and methods did not allow comparisons 
between types of surgical treatment and adjuvant 
therapies.
Authors agree that surgical removal of papillomas 
is the treatment of choice for patients with papillomatosis, 
despite differences between approaches. Larynx 
microsurgery can be performed with cold instruments, 
laser, and, as reported more recently, microdebriders. 
This review revealed that laryngeal sequelae were 
reported in 6% to 61% of the cases, depending on the 
chosen procedure. More recent studies have preferred 
microdebriders to other surgical instruments.
Drugs such as interferon, often described in the 
past, have not been used as adjuvant therapy in recent 
papers, indicating a trend toward the discontinuation of 
this type of therapy.
Although most recent papers still prefer cidofovir 
in the adjuvant therapy of RRP, some studies have failed 
to report significant improvements consequent to the 
use of this medication. In early studies, cidofovir was 
indicated only in local or intralesional treatment. Some 
authors have also described the use of inhaled cidofovir 
(Table 1).
The papers written by Zeitels et al. as of 2009 
have described very positive results for bevacizumab in 
association with KTP laser as an adjuvant therapy14,15. 
However, the low number of studies on Avastin, the 
samples, and methods used in these studies do not allow 
conclusions to be drawn on the effectiveness of this RRP 
adjuvant therapy.
Although the HPV vaccine has been indicated to 
prevent against infection by the four subtypes of HPV 
(6, 11, 16, and 18), it has also been used as adjuvant 
therapy in patients with RRP. In 2008, Förster et al.20 
suggested the vaccine was beneficial for RRP patients and 
called for the organization of a multicenter trial. In 2009, 
Pawlita & Gissmann21 recommended papillomatosis adjuvant 
therapy with tetravalent HPV vaccine. In 2011, Mudry et al.17 
reported the case of a five-year-old submitted to multiple 
procedures for frequently recurring papillomas followed up 
for 17 months who entered remission after taking the HPV 
vaccine. However, this therapy has been described in the 
literature merely in the form of isolated case reports.
DISCUSSION
Disease progress varies in RRP. While some patients 
with laryngeal papillomatosis see their condition regress 
spontaneously, others require multiple procedures for 
decades, with recurrence taking place within less than 
two weeks of surgery. Children usually experience more 
aggressive relapses and have less encouraging prognosis1,2. 
The treatment of RRP can be a significant challenge in ENT 
practice. Although surgery is the treatment of choice, it 
does not prevent lesions from recurring.
Surgery aims to preserve uninvolved tissue, 
completely remove papillomas, and avoid scarring. It 
can be performed with cold instruments, CO
2
 laser, or 
microdebriders1,2,10. New approaches to surgery have 
been developed since cold laryngeal microsurgery. In the 
early 1970s, the advent of laser technology gave birth to 
a new surgical approach believed to offer the following 
Table 1. Results of studies on adjuvant therapy with cidofovir.
Authors Year Mode of administration Results
Snoeck et al. 1998 Local injection +
Pransk et al. 
Pransk et al.
1999 
2000 Local injection
+ 
+
Bielomowicz et al. 2002 Local injection +
Pransky et al. 2003 Local injection +
Lee et al. 2004 Local injection +
Shirley et al. 2004 Local injection -
Avelino et al. 2004 Local injection +
Kimberlin 2004 Local injection +
Pontes et al. 2006 Local injection +
Naiman et al. 2006 Local injection +
Naiman et al. 2006 Local injection +
Dikkers 2006 Local injection +
*Giles et al. 2006 Inhalation +
Pudszhn et al. 2007 Local injection +
Broekema et al. 2008 Local injection +
**McMurray et al. 2008 Local injection -
Pontes et al. 2009 Local injection +
*Ksiazik et al. 2011 Inhalation +
Carneiro et al. 2012 Local injection +
* Case report; ** Randomized double-blind placebo-controlled study.
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advantages: better control over bleeding, higher accuracy, 
and longer disease-free periods. Thus, this approach was 
chosen as the first-line treatment for RRP20-24.
However, the indications and use of CO
2
 laser 
have been challenged in recent years by a number of 
authors. Studies have revealed the procedure presents 
higher risk of respiratory tract burns, and is more prone 
to producing stenosis and severe laryngeal scarring, distal 
injuries with tracheoesophageal fistulae, in addition to 
increasing the cost of treatment when compared to surgery 
with a microdebrider2,25,26. Other authors, such as Morgan 
e Crockett, reported complication rates of 61% and 36% 
with laser surgery, respectively1,2. A retrospective study on 
the complications of CO
2
 laser surgery found that 10 of 
the 17 enrolled subjects had laryngeal scarring27. In 2007, 
Preuss et al.12 reported complication rates of only 6% in 
laser surgery against 20% when using the conventional 
approach.
In this context, microdebrider surgery has conquered 
adepts and is gradually replacing laser surgery as the 
surgical procedure of choice. Some authors have pointed 
out advantages such as shorter time of surgery, lower cost, 
lower risk of complications, and better patient voice quality 
when compared to CO
2
 laser2,12,23. The risk of sequelae 
is believed to vary depending on the type of procedure 
the patients are offered. Therefore, while some authors 
credit laser as the culprit of cases of laryngeal scarring, 
others prefer to defend its use. Nonetheless, regardless of 
the approach/instruments used, the virus remains latent 
even after careful resection, thus leading to recurrence1. 
Managing recurrence often requires extensive manipulation 
of the larynx, and possibly leads to permanent damage 
in the form of stenosis, anterior and posterior membrane 
neoformation, vocal fold injury, and granulation tissue 
formation, among others2. A retrospective study with 50 
children with RRP revealed that laryngeal sequelae occur 
frequently, particularly anterior commissure synechia and 
glottic stenosis1.
Adjuvant therapies gained ground in medical 
practice as an attempt to minimize recurrence, its 
complications, the negative impacts it has upon patients’ 
lives, and reduce or eliminate the need for future surgery. 
The most widely accepted criteria to start adjuvant therapy 
are: need for more than four surgical procedures per year, 
lesions extending toward the subglottic region, and short 
disease-free intervals leading to airway involvement28. 
Between 12.6% and 47.6% of the children with RRP are 
given adjuvant therapy7,10,18,29, as recommended in cases 
of aggressive disease with frequently recurring papillomas 
or distal involvement of the airways10,30.
Interferon-alpha was the first medication offered 
as adjuvant therapy to RRP patients. Although it is still 
used today, interferon-alpha is no longer as popular as it 
once was. In its early days, the drug seemed to produce 
good outcomes, particularly within the first few months 
of use, but patients experienced multiple side effects. 
Other therapies and drugs such as indole-3-carbinol, 
photodynamic therapy, and cis-retinoic acid were studied, 
but none grew to become the therapy of choice for subjects 
with RRP3,10.
In recent years ,  ant iv i ra l  drug cidofovir 
[(S)-1-[(3-hydroxy-2-phosphonyl methoxy) propyl] 
cytosine (HPMPC )] was introduced as a potent replica-
tion inhibitor for HPV, adenovirus, cytomegalovirus, and 
herpesvirus2,10,31-41.
Cidofovir has been used as an adjuvant drug since 
1998. In 1998, Snoeck et al. studied the use of cidofovir 
injections to control RRP in adult subjects, while Pransky 
et al. analyzed its impact on pediatric populations in 
1999 and 200031-33. The drug is a cytosine analog and a 
potent inhibitor of viral replication. Nephrotoxicity is a 
significant, frequently seen side effect described in patients 
on cidofovir. Other adverse effects include neutropenia, 
weakness, nausea, and diarrhea10. However, a study on the 
local administration of cidofovir to treat children with RRP 
did not report alterations in their lab workup or adverse 
effects to the medication, apparently reaffirming the drug’s 
safety when administered locally3,7,32-39. The literature offers 
a vast array of papers on cidofovir. However, favorable 
outcomes (remission or less severe disease in most 
patients)33-39 have been reported along with no significant 
improvements in disease recurrence40,41.
Cidofovir was described as the most used adjuvant 
therapy on a survey carried out with members of the 
American Society of Pediatric Otolaryngology, with 
interferon ranking second. Sixty-one percent of the patients 
followed up in the services of the physicians included in 
the survey improved or were disease-free after treatment, 
against only four percent of cases in which the disease 
became more severe. Nonetheless, this study may contain 
bias and sampling errors, in addition to having used a 
subjective assessment tool to analyze patient responses, 
which may have affected the published results18.
A study carried out by members of the British 
Association of Paediatric Otorhinolaryngology in 2006 
showed that cidofovir was the most frequently prescribed 
drug in the treatment of individuals with RRP. However, the 
study failed to determine the role of cidofovir in the treat-
ment or to quantify decreases in recurrence7. Some authors 
began to wonder whether intralesional cidofovir would 
increase the potential for the development of malignant 
disease. The Food and Drug Administration (FDA) has 
considered cidofovir to be possibly carcinogenic, once 
it increased the incidence of breast adenocarcinoma in 
rats42. Intralesional cidofovir has also been connected 
to cases of dysplasia in human beings43-45. Although 
Broekema reported malignant degeneration in a group of 
patients given 2.7% cidofovir, the author pointed out that 
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spontaneous malignant degeneration occurs in 2-3% of RRP 
patients, thus ruling out the alleged association between 
cidofovir and increased incidence of malignant disease. 
All the more, HPV increases the chance of development of 
malignant disease alone, independently from cidofovir43.
In 2008, Lindsay et al.13 analyzed the histology of 
papillomas before and after the administration of cidofovir 
and did not observe the occurrence of dysplasia in the 
patients. The author also reported that cidofovir could 
potentially cause vocal fold scarring, and suggested the 
drug should be used with caution on the vocal folds13.
Only case reports have described the use of inhaled 
cidofovir in the literature. In 2006, a report was published 
in which inhaled cidofovir was used to reach lung 
lesions43,46. It described the case of an eleven-month-old 
girl with respiratory failure and stridor (due to RRP) who 
underwent a tracheostomy. In order to reach papillomas 
in the lungs, cidofovir was administered with the aid of a 
nebulizer connected to the tracheostomy tube. The only 
reported complication was hemoptysis, which resolved as 
the drug dosage was reduced. The patient responded well, 
and her lower airway lesions shrank to a size invisible to 
the naked eye and the complications disappeared46.
In 2011, another report described the case of a 
previously healthy four-month-old with weak cry, hoarse-
ness, and increased respiratory effort. Examination with 
a flexible fiberscope revealed the patient had papillomas 
in the glottis, which were removed with a microdebrider. 
Despite treatment with a microdebrider every two weeks, 
intralesional cidofovir, and systemic interferon-alpha, the 
patient’s health deteriorated substantially from persistent 
complications. The patient was then offered inhaled 
cidofovir after the failure of conventional therapies. 
Significant improvement was seen after six weeks of tre-
atment. Nonetheless, further studies are needed to look 
into the long-term effectiveness of the treatment and the 
safety profile of inhaled cidofovir47.
According to this literature review, although 
cidofovir is the most frequently used adjuvant therapy, it is 
not universally accepted. The need to find alternative RRP 
adjuvant therapies has recently led to the development of 
new treatment modes with bevacizumab and tetravalent 
HPV vaccine.
Considering the use of bevacizumab (Avastin), this 
review showed that vascularization is believed to be a 
determining factor in how quickly papillomas reappear. 
Thus, bevacizumab would work as an angiogenesis 
inhibitor, to hamper or stop the growth of papillomas and 
associated complications15,16. Complementary modes of 
action and reported safety have led authors to advocate 
the combination of local injections of bevacizumab and 
KTP laser surgery. The clinical successes of bevacizumab 
and KTP laser reported within the last two years and the 
lack of complications after over 200 laryngeal injections of 
bevacizumab have pushed this therapy to the top of the 
list of RRP treatment options15,16. However, larger and more 
significant studies are required to prove the benefits of this 
therapy. Relevant questions have been posed about the 
combined use of bevacizumab and KTP laser. Is activation 
by laser needed for bevacizumab to yield proper benefit? 
Could the drug be used without KTP laser?
Tetravalent HPV vaccine protects against viral sub-
types 6, 11, 16, and 18 and works on an acquired immunity 
mechanism characterized by specificity and memory; it is 
mediated by B-cells, T-cells, antibodies, and cytokines48,49. 
When an antigen gets in touch with these cells, a specific 
response is produced. Then, the antigen produces a strong 
qualitative and quantitative response, with high levels of 
antibodies, thus configuring the immune memory and long-
-term protection. Immunogenicity, the ability to provoke a 
specific immune response, is usually measured as a function 
of antibody counts48. Tetravalent HPV vaccine is a killed 
vaccine, which does not contain antigens able to replicate 
in the individuals given the shot. It is produced using mole-
cular biology techniques. Tetravalent HPV vaccine contains 
particles produced in vitro from viral proteins which are 
similar to the virus. They combine spontaneously to form 
structures similar to the whole virus48,49. It is important to 
note that the vaccine does not have infectious or oncogenic 
potential, and that it is very safe. Clinical trials currently in 
progress have not reported significant adverse events; side 
effects were limited to pain, redness, and edema on the site 
of injection, low fever, headache, and syncope48.
Although vaccination is currently considered only 
for patients not infected by HPV, it has also been studied 
for patients with RRP. In 2008, Förster reported the case 
of a two-year-old with aggressive laryngeal papillomatosis. 
After three shots of tetravalent HPV injection, the patient’s 
condition was stabilized without surgery 10 months into 
follow-up2,20.
In 2009, Pawlita & Gissmann described the use 
of tetravalent HPV vaccine as an adjuvant therapy for 
papillomatosis, reinforcing the role this medication could 
have in infected patients and the very low risks associated 
with its use2,21.
In 2011, Mudry et al. reported the case of a 
five-year-old with frequent recurring papillomas submitted 
to multiple procedures. The patient entered remission 
after the administration of tetravalent HPV vaccine. The 17 
months for which this patient has been disease-free ranks 
as one of the longest periods without disease reported in 
the literature2,17.
Many case report authors have described changes to 
the natural course of the disease, stabilization, or significant 
reductions in papilloma recurrence after vaccination. Howe-
ver, as these are only isolated case reports, comprehensive 
multicenter trials are required to assess the true benefits of 
vaccination in the treatment of RRP16,17,20,21.
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This literature review indicated that the use of 
surgery and adjuvant therapies largely depends on the 
context of each service, the experience of the physicians 
involved, the possible adverse effects and, mainly, the 
acceptance of patients, and not only on how effective the 
treatment can be.
CONCLUSION
This literature review showed there is no consensus 
around one surgical approach for RRP, despite a recent 
trend toward the use of microdebriders. In regards 
to adjuvant therapies, although cidofovir is the most 
frequently used drug, large multicenter trials are required 
to better describe the levels of efficacy offered by this drug.
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